AI MARKET SCANNING

Altimmune, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.83%
MAX GAP RECORD +7.75%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ALT
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 12, 2026 Earnings Release 2026-08-12 (BEFORE OPEN)
+1.67%
May 13, 2026 Earnings Release 2026-05-13 (UNDETERMINED)
+0.00%
Mar 05, 2026 Earnings Release 2026-03-05 (BEFORE OPEN)
-3.98%
Nov 06, 2025 Earnings Release 2025-11-06 (BEFORE OPEN)
+1.87%
Aug 12, 2025 Earnings Release 2025-08-12 (BEFORE OPEN)
+3.85%
May 13, 2025 Earnings Release 2025-05-13 (BEFORE OPEN)
+1.03%
Feb 27, 2025 Earnings Release 2025-02-27 (AFTER CLOSE)
-2.73%
Nov 12, 2024 Earnings Release 2024-11-12 (AFTER CLOSE)
+2.74%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.2%
Bullish Gaps (10)
Bearish Gaps (3)
Neutral / Flat (0)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ALT

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗